Ryohei Nagai

Ryohei Nagai

Auto-generated profile, based on publicly available information

Ryohei Nagai

Pharmaceutical Research Division, Shionogi & Co., Ltd., Osaka, Japan

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 July 2023 in Molecular Cancer Therapeutics
Verified
Journal Article
Open access
PDF file
YNYoji Nagira
Yoji Nagira
MNMorio Nagira
Morio Nagira
RNRyohei Nagai
Ryohei Nagai
WNWataru Nogami
Wataru Nogami
MHMichinari Hirata
Michinari Hirata
HTHidekazu Tanaka
Hidekazu Tanaka
Although regulatory T cells (Treg) are inhibitory immune cells that are essential for maintaining immune homeostasis, Tregs that infiltrate tumor tissue promote tumor growth by suppressing antitumor immunity. Selective reduction of tumor-infiltrating Tregs is, therefore, expected to activate antitumor immunity without affecting immune homeostasis. We previously reported that selective Treg depletion targeted by a C-C motif chemokine receptor 8 (CCR8) resulted in induction of strong antitumor immunity without any obvious autoimmunity in mouse models. Thus, herein, we developed a novel humanized anti-CCR8 monoclonal antibody, S-531011, aimed as a cancer immunotherapy strategy for patients with cancer. S-531011 exclusively recognized human CCR8 among all chemokine receptors and showed potent antibody-dependent cell-mediated cytotoxicity activity toward CCR8+ cells and neutralization activity against CCR8-mediated signaling. We observed that S-531011 reduced tumor-infiltrating CCR8+ Tregs and induced potent antitumor activity in a tumor-bearing human-CCR8 knock-in mouse model. Moreover, combination therapy with S-531011 and anti-mouse programmed cell death 1 (PD-1) antibody strongly suppressed tumor growth compared with anti–PD-1 antibody alone with no observable adverse effects. S-531011 also depleted human tumor-infiltrating Tregs, but not Tregs derived from human peripheral blood mononuclear cells. These results suggest that S-531011 is a promising drug for inducing antitumor immunity without severe side effects in the clinical setting.

27 November 2025
Verified
Other
Open access
YNYoji Nagira
Yoji Nagira
MNMorio Nagira
Morio Nagira
RNRyohei Nagai
Ryohei Nagai
WNWataru Nogami
Wataru Nogami
MHMichinari Hirata
Michinari Hirata
HTHidekazu Tanaka
Hidekazu Tanaka
In vivo anti-tumor activity of S-531011 in CT26.WT or EMT6 tumor-bearing mice model.


27 November 2025
Verified
Other
Open access
YNYoji Nagira
Yoji Nagira
MNMorio Nagira
Morio Nagira
RNRyohei Nagai
Ryohei Nagai
WNWataru Nogami
Wataru Nogami
MHMichinari Hirata
Michinari Hirata
HTHidekazu Tanaka
Hidekazu Tanaka
Although regulatory T cells (Treg) are inhibitory immune cells that are essential for maintaining immune homeostasis, Tregs that infiltrate tumor tissue promote tumor growth by suppressing antitumor immunity. Selective reduction of tumor-infiltrating Tregs is, therefore, expected to activate antitumor immunity without affecting immune homeostasis. We previously reported that selective Treg depletion targeted by a C-C motif chemokine receptor 8 (CCR8) resulted in induction of strong antitumor immunity without any obvious autoimmunity in mouse models. Thus, herein, we developed a novel humanized anti-CCR8 monoclonal antibody, S-531011, aimed as a cancer immunotherapy strategy for patients with cancer. S-531011 exclusively recognized human CCR8 among all chemokine receptors and showed potent antibody-dependent cell-mediated cytotoxicity activity toward CCR8+ cells and neutralization activity against CCR8-mediated signaling. We observed that S-531011 reduced tumor-infiltrating CCR8+ Tregs and induced potent antitumor activity in a tumor-bearing human-CCR8 knock-in mouse model. Moreover, combination therapy with S-531011 and anti-mouse programmed cell death 1 (PD-1) antibody strongly suppressed tumor growth compared with anti–PD-1 antibody alone with no observable adverse effects. S-531011 also depleted human tumor-infiltrating Tregs, but not Tregs derived from human peripheral blood mononuclear cells. These results suggest that S-531011 is a promising drug for inducing antitumor immunity without severe side effects in the clinical setting.